Australia markets closed
  • ALL ORDS

    7,543.60
    +7.50 (+0.10%)
     
  • ASX 200

    7,241.20
    +16.00 (+0.22%)
     
  • AUD/USD

    0.7004
    -0.0090 (-1.27%)
     
  • OIL

    66.22
    -0.28 (-0.42%)
     
  • GOLD

    1,782.10
    +21.40 (+1.22%)
     
  • BTC-AUD

    70,226.97
    -6,821.00 (-8.85%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • AUD/EUR

    0.6187
    -0.0087 (-1.39%)
     
  • AUD/NZD

    1.0371
    -0.0028 (-0.27%)
     
  • NZX 50

    12,676.50
    +6.26 (+0.05%)
     
  • NASDAQ

    15,712.04
    -278.72 (-1.74%)
     
  • FTSE

    7,122.32
    -6.89 (-0.10%)
     
  • Dow Jones

    34,580.08
    -59.71 (-0.17%)
     
  • DAX

    15,169.98
    -93.13 (-0.61%)
     
  • Hang Seng

    23,766.69
    -22.24 (-0.09%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     

Global Atypical Hemolytic Uremic Syndrome Market to 2030 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com

·5-min read

DUBLIN, October 25, 2021--(BUSINESS WIRE)--The "Atypical Hemolytic Uremic Syndrome(aHUS) - Market Insight, Epidemiology and Market Forecast -2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Atypical Hemolytic Uremic Syndrome market report provides current treatment practices, emerging drugs, Atypical Hemolytic Uremic Syndrome market share of the individual therapies, current and forecasted Atypical Hemolytic Uremic Syndrome market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Atypical Hemolytic Uremic Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Companies Mentioned

  • Alexion Pharmaceuticals

  • Omeros Corporation

  • Novartis Pharmaceuticals

  • Hoffmann-La Roche

  • Chugai Pharmaceutical

Key Findings

The Atypical Hemolytic Uremic Syndrome (aHUS) market size in the 7MM is expected to change during the study period 2018-2030. The therapeutic market of Atypical Hemolytic Uremic Syndrome in the seven major markets is expected to increase during the study period (2018-2030) with a CAGR of 3.3%. According to the estimates, the highest market size of Atypical Hemolytic Uremic Syndrome is found in the United States followed by Germany.

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Atypical Hemolytic Uremic Syndrome market.

  • To understand the future market competition in the Atypical Hemolytic Uremic Syndrome market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for Atypical Hemolytic Uremic Syndrome in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

  • Organize sales and marketing efforts by identifying the best opportunities for the Atypical Hemolytic Uremic Syndrome market.

  • To understand the future market competition in the Atypical Hemolytic Uremic Syndrome market.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance

4. Executive Summary of Atypical Hemolytic Uremic Syndrome (aHUS)

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Types of Hemolytic Uremic Syndrome

6.3. Risk Factors and Causes of Atypical Hemolytic Uremic Syndrome

6.4. Signs and Symptoms of Atypical Hemolytic Uremic Syndrome

6.5. Pathophysiology of Atypical Hemolytic Uremic Syndrome

6.6. Complement Protein Mutations

6.7. Clinical Manifestations of Atypical Hemolytic Uremic Syndrome

7. Diagnosis and Differential Diagnosis of Atypical Hemolytic Uremic Syndrome

7.1. Diagnostic Algorithm of Atypical Hemolytic Uremic Syndrome

7.2. Blood Tests

7.3. Specific Testing

7.4. Genetic Testing

7.5. Differential Diagnosis

8. Diagnostic Guidelines

8.1. The Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society

8.2. Clinical Practice Guidelines for the management of atypical Hemolytic Uremic Syndrome in the United Kingdom

9. Current Treatment Practices of Atypical Hemolytic Uremic Syndrome

9.1. Treatment Algorithm of Atypical hemolytic uremic syndrome

9.1.1. Plasma Exchange

9.1.2. Eculizumab

9.1.3. Ravulizumab

9.1.4. Kidney Transplant

9.1.5. Liver transplantation

10. Treatment Guidelines

10.1. The European Rare Kidney Disease Reference Network guidelines to the management of atypical hemolytic uremic syndrome in children

10.2. Clinical Practice Guidelines for the management of atypical Hemolytic Uremic Syndrome in the United Kingdom

10.3. National Institute for Health and Research

11. Conclusion

12. Epidemiology and Patient Population

12.1. Key Findings

12.2. Epidemiology of Atypical Hemolytic Uremia Syndrome

12.3. Epidemiology Scenario

12.3.1. Total Prevalent Cases of Atypical Hemolytic Uremia Syndrome

12.3.2. Total Diagnosed Cases of Atypical Hemolytic Uremia Syndrome

12.3.3. Total Age group-specific Cases of Atypical Hemolytic Uremia Syndrome

12.3.4. Total Treated Cases of Atypical Hemolytic Uremia Syndrome

13. Patient Journey

14. Key Endpoints in Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trials

15. Marketed Therapies

15.1. Soliris (Eculizumab): Alexion Pharmaceuticals

15.1.1. Drug Description

15.1.2. Regulatory Milestones

15.1.3. Other Developmental Activities

15.1.4. Pivotal Clinical Trial

15.2. Ultomiris (Ravulizumab): Alexion Pharmaceuticals

15.2.1. Drug Description

15.2.2. Regulatory Milestones

15.2.3. Other Developmental Activities

15.2.4. Pivotal Clinical Trial

15.2.5. Ongoing Current Pipeline Activity

16. Emerging Therapies

16.1. Narsoplimab (OMS721): Omeros Corporation

16.1.1. Product Description

16.1.2. Other Developmental Activities

16.1.3. Clinical Developmental Activities

16.1.4. Safety and Efficacy

16.2. Iptacopan (LNP 023): Novartis Pharmaceuticals

16.2.1. Product Description

16.2.2. Clinical Developmental Activities

16.3. Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical

16.3.1. Product Description

16.3.2. Clinical Developmental Activities

17. Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis

18. Market Access and Reimbursement

19. KOL Views

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Unmet Needs

24. Appendix

25. Disclaimer

26. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/hi7rxa

View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005391/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting